Cargando…
A prospective study of salvational intervention with ICS/LABA for reducing chronic obstructive pulmonary disease exacerbation under severe air pollution (SIRCAP) in Beijing: protocol of a multi-center randomized controlled trial
BACKGROUND: Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality all over the world. Acute exacerbation of COPD (AECOPD) not only accelerates the progression of disease, but also causes hospital administration and death events. Epidemiologic studies have shown air...
Autores principales: | Zhou, Tianyu, Zhong, Yijue, Liao, Jiping, Wang, Guangfa, Li, Xueying, Qian, Xiaosen, Xiang, Pingchao, Chen, Xinsheng, Xu, Zhenyang, Zhang, Fengzhen, Wang, Xiaoguang, Wang, Senlin, Li, Xiangxin, Yu, Chunxiao, Zhang, Yongxiang, Xia, Guoguang, Dai, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347780/ https://www.ncbi.nlm.nih.gov/pubmed/30683080 http://dx.doi.org/10.1186/s12890-018-0771-9 |
Ejemplares similares
-
EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
por: Buhl, Roland, et al.
Publicado: (2023) -
LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes
por: Hizawa, Nobuyuki
Publicado: (2015) -
Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler
por: Price, David B., et al.
Publicado: (2016) -
Predictive Value of Combining Inflammatory Biomarkers and Rapid Decline of FEV(1) for COPD in Chinese Population: A Prospective Cohort Study
por: Wang, Yunxia, et al.
Publicado: (2019) -
Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
por: Singh, Dave, et al.
Publicado: (2019)